Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in PediatricsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The past and future of haemophilia: diagnosis, treatments, and its complications.Lancet. 2016; 388: 187-197
- Factor VIII: structure and function in blood clotting.Am J Hematol. 1984; 16: 297-306
- Evaluation of CDC's hemophilia surveillance program - universal data collection (1998-2011) and community counts (2011-2019), United States.MMWR Surveill Summ. 2020; 69: 1-18
- Occurrence of hemophilia in the United States. the hemophilia surveillance system project investigators.Am J Hematol. 1998; 59: 288-294
- Bleeding in carriers of hemophilia.Blood. 2006; 108: 52-56
- Hemophilia A in females: considerations for clinical management.Acta Haematol. 2020; 143 (d): 289-294
- MASAC document 264 - MASAC recommendations regarding diagnosis and management of inherited bleeding disorders in girls and women with personal and family history of bleeding.(Available at:) (Accessed September 15, 2021)
- Definitions in hemophilia: communication from the SSC of the ISTH.J Thromb Haemost. 2014; 12: 1935-1939
- Bleeding disorders: characterization, dental considerations and management.J Can Dent Assoc. 2006; 72: 827
- WFH guidelines for the management of hemophilia, 3rd edition.Haemophilia. 2020; 26: 1-158
- Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.N Engl J Med. 2007; 357: 535-544
- Optimal haemophilia care versus the reality.Br J Haematol. 2006; 132: 671-682
- Modern treatment of haemophilia.Bull World Health Organ. 1995; 73: 691-701
- Principles of haemophilia care: the Asia-Pacific perspective.Haemophilia. 2018; 24: 366-375
- Mortality among males with hemophilia: relations with source of medical care. the hemophilia surveillance system project investigators.Blood. 2000; 96: 437-442
- A practical guide to the management of the fetus and newborn with hemophilia.Clin Appl Thromb Hemost. 2018; 24: 29S-41S
- MASAC document 221 - recommendations on administration of vaccines to individuals with bleeding disorders.(Available at) (Accessed September 17, 2021)
- Standard and water rehabilitation: An analysis of over 14 years' experience in patients with haemophilia or other clotting factor disorders after orthopaedic surgery.Haemophilia. 2019; 25: 699-707
- The effect of aquatic exercise therapy on muscle strength and joint's range of motion in hemophilia patients.Int J Prev Med. 2013; 4: 50-56
- Oral care for people with hemophilia or a hereditary bleeding tendency.2nd edition. World Federation of Hemophilia, 2008 (Available at:) (Accessed September 18, 2021)
- Access to primary dental care for patients with inherited bleeding disorders.Haemophilia. 2012; 18: 510-515
- Guidance on the dental management of patients with haemophilia and congenital bleeding disorders.Br Dent J. 2013; 215: 497-504
- Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs.Haemophilia. 2007; 13: 279-286
- Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia.Haemophilia. 2006; 12: 514-517
- Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy.Blood. 2006; 107: 1785-1790
- Recommendations on multidisciplinary management of elective surgery in people with haemophilia.Haemophilia. 2018; 24: 693-702
- Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.Blood. 1997; 90: 2515-2521
- Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A.Br J Haematol. 2017; 176: 796-804
- Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens.Blood. 2015; 125: 2038-2044
- Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized.Br J Haematol. 1999; 105: 1109-1113
- Young adult outcomes of childhood prophylaxis for severe hemophilia a: results of the joint outcome continuation study.Blood Adv. 2020; 4: 2451-2459
- New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.Haemophilia. 2010; 16: 256-262
- Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia a: the CANAL cohort study.Blood. 2007; 109: 4648-4654
- Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia a: the RODIN study.Blood. 2013; 121: 4046-4055
- Products licensed in the US.(Available at) (Accessed August 2, 2021)
- Extended half-life factor VIII and factor IX preparations.Transfus Med Hemother. 2018; 45: 86-91
- Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.Haemophilia. 2016; 22: 389-396
- BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A.N Engl J Med. 2020; 383: 1018-1027
- Impact of inhibitors on hemophilia A mortality in the United States.Am J Hematol. 2015; 90: 400-405
- The socioeconomic burden of patients affected by hemophilia with inhibitors.Eur J Haematol. 2018; 101: 435-456
- The epidemiology of inhibitors in haemophilia A: a systematic review.Haemophilia. 2003; 9: 418-435
- Improvements in factor VIII inhibitor detection: from bethesda to nijmegen.Semin Thromb Hemost. 2009; 35: 752-759
- Recommendations for assessment, monitoring and follow-up of patients with haemophilia.Haemophilia. 2012; 18: 319-325
- How I treat children with haemophilia and inhibitors.Br J Haematol. 2019; 186: 400-408
- Immune tolerance induction: what have we learned over time?.Haemophilia. 2018; 24: 3-14
- US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors.Haemophilia. 2015; 21: 559-567
- How we treat a hemophilia A patient with a factor VIII inhibitor.Blood. 2009; 113: 11-17
- A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.Blood. 2007; 109: 546-551
- Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.N Engl J Med. 2011; 365: 1684-1692
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.Nat Med. 2012; 18: 1570-1574https://doi.org/10.1038/nm.2942
- MASAC document 258 - Recommendation on the use and management of emicizumab-kxwh (hemlibra®) for hemophilia A with and without inhibitors.(Available at) (Accessed August 20, 2021)
- Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?.Blood. 2017; 130: 2463-2468
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors.N Engl J Med. 2017; 377: 809-818
- The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.Haemophilia. 2019; 25: 33-44
- Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.Lancet Haematol. 2019; 6: e295-e305
- A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.Blood. 2019; 134: 2127-2138
- ST-segment elevation myocardial infarction (STEMI) and pulmonary embolism in a hemophilia A patient receiving emicizumab and recombinant activated factor VII.Haemophilia. 2020; 26: e5-e8
- Sequential bypassing agents during major orthopedic surgery: a new approach to hemostasis.Blood Adv. 2017; 1: 1309-1311
- Emicizumab should be prescribed independent of immune tolerance induction.Blood Adv. 2018; 2: 2783-2786
- Gene therapy for hemophilia.Hematology Am Soc Hematol Educ Program. 2019; 2019: 1-8
- Update on clinical gene therapy for hemophilia.Blood. 2019; 133: 407-414
- Discussing investigational AAV gene therapy with hemophilia patients: a guide.Blood Rev. 2021; 47: 100759
- Entering the modern era of gene therapy.Annu Rev Med. 2019; 70: 273-288
- Adenoviral vectors for hemophilia gene therapy.J Genet Syndr Gene Ther. 2013; 2: 017
- Gene Therapy.N Engl J Med. 2019; 381: 455-464
- AAV5-factor VIII gene transfer in severe hemophilia A.N Engl J Med. 2017; 377: 2519-2530
- Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A.N Engl J Med. 2020; 382: 29-40
- Phase I/II trial of SPK-8011: stable and durable FVIII expression after AAV gene transfer for hemophilia A [abstract].Res Pract Thromb Haemost. 2021; 5 (Available at)
- Recent advances in gene therapy for hemophilia clinical trials.(Available at) (Accessed November 15, 2021)
- Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.Nat Med. 2006; 12: 342-347
- Adeno-associated mediated gene transfer for hemophilia B:8 year follow up and impact of removing “empty viral particles” on safety and efficacy of gene transfer.Blood. 2018; 132: 491
- AAV vector integration sites in mouse hepatocellular carcinoma.Science. 2007; 317: 477
Article info
Publication history
Published online: June 20, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
